RxLogix

RxLogix develops a pharmacovigilance (PV) software platform delivered as a SaaS solution, serving pharmaceutical companies, contract research organisations (CROs), vaccine manufacturers, and medical device companies. The platform is described as an end-to-end system built on a single governed data model, covering the full drug safety lifecycle from case intake through signal detection, risk management, and regulatory reporting. RxLogix states it is trusted by top-20 pharma organisations and has processed over 10 million cases annually and generated more than 55,000 reports monthly.

The platform incorporates AI, machine learning, and natural language processing (NLP) capabilities — referred to as RxLogix Agentic AI — embedded directly into workflows and designed for regulated production environments. Reported performance metrics include 60–80% fewer manual touchpoints, 80% faster reporting, 40–60% fewer false positives in signal detection, 25% more unique signals detected, 30–50% operational cost reduction, and 96% consistency against benchmarks. The system is described as audit-ready by design and compliant with regulatory requirements without requiring workarounds.

Core Platform Modules

• Case and PQC Intake: Automated ingestion of individual case safety reports and product quality complaints.
• Case and Complaint Management: End-to-end management of adverse event cases and product complaints within a unified data model.
• Safety Reporting and Analytics: Generation and submission of regulatory safety reports, with analytics capabilities built in.
• Signal Detection and Management: AI-assisted detection and management of safety signals, including signalling on real-world data (RWD) and clinical data.
• Risk Identification and Management: Tools for identifying and managing product risk across the safety lifecycle.
• Compliance Monitoring: Ongoing monitoring of regulatory compliance obligations.
• Quality Monitoring: Oversight of data and process quality within PV operations.
• Content Authoring and Publishing: Authoring and publishing of safety-related regulatory documents and content.

AI and Technology Capabilities

• Agentic AI, ML, and NLP integrated directly into production workflows rather than as standalone pilots or demonstrations.
• Governed, explainable, and auditable AI designed to meet regulatory expectations.
• True data interoperability described as the only platform offering unified data across all modules.
• Signal detection capabilities delivering 2–3 times faster true signal identification and reduced cost per signal.
• Validation and traceability built into the platform architecture to support audit readiness.

Deployment and Operations

• Delivered as a SaaS platform with cloud operations infrastructure described as high-performance and evidentiary-grade.
• Designed for compliance by default, with no requirement for time-consuming regulatory workarounds.
• Global deployments across pharma, biotech, and regulated environments.
• Single application layer across all modules, eliminating the need for point solutions or downstream data stitching.

Services and Customer Profile

• RxLogix offers professional services and solutions alongside the software platform.
• Customers include top-20 pharmaceutical companies, CROs, vaccine manufacturers, and medical device organisations.
• Reported customer outcomes include a 60% reduction in case processing time and compilation tasks reduced from days to minutes.
• The company positions its return on investment as measurable within months rather than years, with a 40% cost reduction cited as a representative outcome.
• RxLogix describes itself as award-winning software with a global presence.

RxLogix positions itself as a specialist PV platform provider focused on consolidating fragmented safety data into a single governed system, with the stated goal of reducing operational cost and complexity while improving signal detection accuracy and regulatory compliance for life sciences organisations worldwide.